Article Text
PDF
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q Does methylphenidate hydrochloride reduce hyperactivity and impulsiveness in children with pervasive development disorder?
METHODS
Design:
Crossover randomised controlled trial.
Allocation:
Concealed.
Blinding:
Double blind.
Follow up period:
Four weeks.
Setting:
Five university outpatient centres, USA; recruitment November 2001 to September 2003.
Patients:
Sixty six children (89% male) aged 5–14 years with DSM-IV autism, Asperger’s syndrome, or unidentified pervasive development disorder plus hyperactivity and/or impulsiveness for ⩾6 months with onset before age 7. Exclusions: receiving psychotropic medication in previous 1–3 weeks; mental age <18 months; other neuropsychiatric disorders; moderate or severe tic disorder; seizures in the past six months; hypertension; other serious medical comorbidity; methylphenidate treatment in previous two years; previous adverse reaction to …
Footnotes
For correspondence: David J Posey, MD, Riley Hospital for Children, Room 4300, 702 Barnhill Drive, Indianapolis, IN 46202, USA; dposey{at}iupui.edu
Sources of funding: Korczak Foundation, Netherlands and National Institute of Mental Health and National Institute of Health, USA.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.